Pros | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | - |
INDMoney rank | 7/8 | 1/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 12 Years | 12 Years | ||
Fund Size | 8161 Cr | 3522 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹500 Lumpsum ₹5000 | ||
Expense Ratio | 0.93% | 0.89% | ||
Exit Load | 1% | 0.5% | ||
Benchmark Index | S&P BSE Healthcare PR | S&P BSE Healthcare PR |
No of Holdings | 40 | 32 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (14.01%) Divi's Laboratories Ltd (9.23%) Lupin Ltd (8.16%) Cipla Ltd (5.62%) Dr Reddy's Laboratories Ltd (5.46%) | Sun Pharmaceuticals Industries Ltd (13.86%) Max Healthcare Institute Ltd Ordinary Shares (6.63%) Divi's Laboratories Ltd (6.18%) Cipla Ltd (5.04%) Lupin Ltd (4.96%) | ||
No of Sectors | 1 | 3 | ||
Top 3 Sectors | Health (100%) | Health (93.02%) Basic Materials (6.98%) Government (4.62%) | ||
Equity % | 98.64% | 98.2% | ||
Debt % | - | 0.08% | ||
P/E | 37.43 | 44.54 | ||
P/B | 6.11 | 6.28 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -5.88% | -7.05% | ||
3-Month Return | -11.35% | -9.2% | ||
6-Month Return | -12.51% | -5.73% | ||
1-Year Return | 6.07% | 12.8% | ||
3-Year Return | 18.44% | 22.79% | ||
5-Year Return | 24.86% | 26.31% |
Sharpe | 0.77 | 1.06 | ||
Alpha | -0.03 | 5.14 | ||
Beta | 0.93 | 0.84 | ||
Standard Deviation | 15.64 | 14.61 | ||
Information Ratio | -0.32 | 1.01 |
Description | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | SBI Healthcare Opportunities Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Sailesh Raj Bhan,Kinjal Desai | Tanmaya Desai |